Solid Biosciences (SLDB) Equity Ratio (2017 - 2026)
Quarterly results put Equity Ratio at 0.88 for Q1 2026, up 3.32% from a year ago — trailing twelve months through Mar 2026 was 0.88 (up 3.32% YoY), and the annual figure for FY2025 was 0.77, up 6.41%.
Solid Biosciences has reported Equity Ratio over the past 10 years, most recently at 0.88 for Q1 2026.
- Equity Ratio reached 0.88 in Q1 2026 per SLDB's latest filing, up from 0.77 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.89 in Q1 2022 and bottomed at 0.73 in Q4 2024.
- Median Equity Ratio over the past 5 years was 0.8 (2023), compared with a mean of 0.81.
- The largest annual shift saw Equity Ratio decreased 13.42% in 2022 before it grew 6.41% in 2025.
- Over 5 years, Equity Ratio stood at 0.81 in 2022, then fell by 5.71% to 0.77 in 2023, then fell by 5.13% to 0.73 in 2024, then increased by 6.41% to 0.77 in 2025, then increased by 14.29% to 0.88 in 2026.
- Business Quant data shows Equity Ratio for SLDB at 0.88 in Q1 2026, 0.77 in Q4 2025, and 0.8 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 0.04 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 0.42 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 0.73 |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 0.77 |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 0.21 |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - | 0.88 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.88 |
| Dec 31, 2025 | 0.77 |
| Sep 30, 2025 | 0.80 |
| Jun 30, 2025 | 0.84 |
| Mar 31, 2025 | 0.86 |
| Dec 31, 2024 | 0.73 |
| Sep 30, 2024 | 0.79 |
| Jun 30, 2024 | 0.84 |
| Mar 31, 2024 | 0.85 |
| Dec 31, 2023 | 0.77 |
| Sep 30, 2023 | 0.78 |
| Jun 30, 2023 | 0.80 |
| Mar 31, 2023 | 0.80 |
| Dec 31, 2022 | 0.81 |
| Sep 30, 2022 | 0.78 |
| Jun 30, 2022 | 0.78 |
| Mar 31, 2022 | 0.89 |
| Dec 31, 2021 | 0.90 |
| Sep 30, 2021 | 0.90 |
| Jun 30, 2021 | 0.89 |
| Mar 31, 2021 | 0.89 |
| Dec 31, 2020 | 0.77 |
| Sep 30, 2020 | 0.55 |
| Jun 30, 2020 | 0.70 |
| Mar 31, 2020 | 0.76 |
| Dec 31, 2019 | 0.77 |
| Sep 30, 2019 | 0.83 |
| Jun 30, 2019 | 0.79 |
| Mar 31, 2019 | 0.82 |
| Dec 31, 2018 | 0.90 |
| Sep 30, 2018 | 0.93 |
| Jun 30, 2018 | 0.95 |
| Mar 31, 2018 | 0.95 |
| Dec 31, 2017 | -0.78 |